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RResults: Procedural success was 99% and 30-days mortality was 1.8%. Adverse
events included: IABP support (13%), renal replacement therapy (6%), infections
(3.6%). No cerebrovascular events or AMI occurred. Median length of hospital stay
was 5 days. At discharge, 87% patients had MR  2+. At 1 year months EF was
34.710.4% (p¼0.002 compared to baseline value). Actuarial survival at 1 year was
89.63%. Actuarial freedom from MR3+ at 1 year was 79.44%. At 1 year,
MLHFQ improved from 4015 to 2216 (p<0.0001). Complete QoL restoration at 1
year was achieved in 43% of the survivors. At multivariate analysis, preoperative
value of serum pro-BNP1600 pg/ml was identiﬁed as independent predictors of QoL
restoration at 1 year (OR 0.2; p¼0.03).
Conclusions:MitraClip therapy is a safe and effective therapeutic option for high-risk
patients with FMR, leading to clinical and QoL improvements. Higher pro-BNP levels
are associated with reduced likelihood of QoL restoration at 1 year.
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Background: The MitraClip device has been used as a percutaneous therapy for both
functional and degenerative mitral regurgitation (MR). However, the actual impact of
the etiology of MR on safety and efﬁcacy outcomes has not been well elucidated. We
aim to describe the differences in experience and outcomes with the MitraClip in both
functional and degenerative MR.
Methods: The MitraClip Asia-Paciﬁc Registry (MARS) registry is a multi-centre
registry involving 6 different centres in the Asia-Paciﬁc region (Singapore, Malaysia,
Australia), collecting information on patients with 3+ MR who have undergone the
MitraClip procedure. Primary efﬁcacy outcome measured was a reduction in MR to
2+ at 30 days. The safety outcomes was 30-day freedom from major adverse events
(MACE), including mortality, myocardial infarction, non-elective cardiac surgery for
adverse events, renal failure, transfusion of 2 units of blood, ventilation for >48 h,
septicaemia, and new onset of atrial ﬁbrillation.
Results: A total of 125 patients (age 71.811.9years, 79 males) were included. Sixty-
four (51.2%) patients had functional MR and 61 (48.8%) had degenerative MR. Thirty
one (48.4%) of functional MR patients had 2 clips inserted compared to 34 (56.7%)
degenerative MR patients (p¼0.375). Acute procedural success was similar in both
functional and degenerative MR (95.3% (61/64) vs 90.2% (55/61), p¼0.316). 71.9%
(46/64) of functional MR had a reduction in MR to 2+ at 30 days compared to
70.5% (43/61) of degenerative MR (p¼0.510). There was no signiﬁcant difference in
both 30-day MACE (7.8% (n¼5) vs 14.8% (n¼9), p¼0.264) as well as 30-day
mortality rates (4.7% (n¼3) vs 6.6% (n¼4), p¼0.713) between functional and
degenerative MR.
Conclusions: The MitraClip procedure has similarly good short-term efﬁcacy and
safety outcomes in the treatment of both functional and degenerative MR.
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Background: Percutaneous edge-to-edge mitral valve repair with the MitraClip
device has been shown to be effective in reducing the severity of mitral regurgitation
(MR), with resultant improvements in clinical outcomes. However, the actual changes
in mitral annular geometry has not been well described. We aim to describe the effects
of the MitraClip on the mitral annular geometry in both functional and degenerative
mitral regurgitation
Methods: 33 consecutive patients (age 7210 yr, 18 males) with 3+ MR, who
underwent MitraClip procedure, were assessed with 3D transesophageal echocardi-
ography before and immediately after the procedure. Specialised software (4D MV-
Assessment, TomTec, GmbH) was used to process the images to obtain the following
mitral annular parameters: anterior-posterior (AP) diameter, intercommissural diam-
eter, 3D circumference (3D-C), 3D area (3D-A) and sphericity index (ratio of AP to
intercommisural diameter).
Results: Thirteen (39.4%) patients had functional MR and 20 (60.6%) had degener-
ative MR. Twenty seven (81.8%) patients had a 2-grade reduction in MR while theJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrremainder had a 1-grade reduction. In patients with functional MR, there was
a signiﬁcant reduction in AP diameter (3.90.5 vs 3.50.4cm, p<0.001), inter-
commisural diameter (4.30.4 vs 3.90.5cm, p¼0.006), 3D-C (13.41.3 vs
12.61.3cm, p¼0.011) and 3D-A (13.72.8 vs 11.52.6cm2, p<0.001). There was
no signiﬁcant change in sphericity index. Similarly, in patients with degenerative MR,
there was a signiﬁcant reduction in AP diameter (3.80.6 vs 3.40.5cm, p<0.001),
intercommisural diameter (4.20.6 vs 3.70.5cm, p<0.001), 3D-C (13.41.9 vs
12.11.4cm, p<0.001) and 3D-A (13.53.8 vs 10.72.6cm2, p<0.001). There was
no signiﬁcant change in sphericity index. Comparing patients with functional vs.
degenerative MR, there was no signiﬁcant difference in the degree of change for all
the above parameters.
Conclusions: Percutaneous edge-to-edge mitral valve repair results in acute changes
in mitral annular geometry in both functional and degenerative MR. The actual impact
of these geometrical changes on procedural success and durability of MR reduction
requires further investigation.
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Background: MitraClip therapy is an emerging option for high-risk patients with
functional mitral regurgitation (FMR). We compare MitraClip outcomes in idiopathic
(ID) and ischemic (IS) MR.
Methods: From October 2008, 109 patients underwent MitraClip for FMR at our
Institution. All patients underwent a standardized prospective data collection
pathway.
Results: Patients were 27 ID (24.8%) and 82 IS (75.2%). Groups did not differ in
age (p¼0.13), NYHA (p¼0.16) and pro-BNP (p¼0.47). ID were slightly "lower-
risk" due to less comorbidities: STS mortality 8.2% vs 11.5% (p¼0.06), REDO
3.2% vs 40.7% (p¼0.0004), COPD 11.1% vs 32.9 (p¼0.02), mean creatinine
1.30.5 vs 1.650.9 mg/dL(p¼0.04), inotropic support(0% vs 9.7%, p¼0.03). ID
however had a more impaired QoL (mean MLHFQ 4816 vs 3713, p¼0.0008;
SF36-F 297 vs 358, p¼0.004; SF36-M 389 vs 399; 6MWT 16876 vs
202109 m, p¼0.08) and a deeper heart dysfunction: mean EF 249% vs
3011%, p¼0.02; EDD 697 vs 678 mm(p¼0.20). Implantation was successful
in 100% vs 98.8%(p¼0.56) and multiple clips were used in 77.8% vs 67.1%
(p¼0.19) of ID and IS respectively. Residual MR>2 was 11% vs 7.5% (p¼0.26).
There was no difference in procedural time, post-operative length of stay and
complications (all p>0.05). In-hospital mortality was 0% in ID vs 2 in IS patients
(p¼0.41). Twenty-two ID and 64 IS reached 1-year follow-up: survival was 86.4%
vs 90.6% (p¼0.57), MR2 78% vs 80% (p¼0.81) respectively. Similar outcomes
were also observed regarding NYHA (18% vs 9%, p¼0.26), MLHFQ (2617 vs
2117, p¼0.16), SF36-F (4111 vs 449, p¼0.14), SF36-M (4711 vs 4810,
p¼0.30) and 6MWT (33694 vs 32978, p¼0.59). All improvements were
statistically signiﬁcant compared to baseline, both in ID and IS (all p<0.05). At 1
year ID and IS had similar EDD (6610 vs 638, p¼0.21), but improvement
appeared signiﬁcant only in the IS (p¼0.19 vs p¼0.0004). EF recovery was also
reduced in the ID vs IS (266 vs 3611, p¼0.0016; respectively p¼0.13 and
p¼0.0036 against baseline).
Conclusions: MitraClip in ID is safe and effective in MR reduction and symptoms
relief at 1-year, providing similar outcomes compared to IS. Ventricle remodeling and
EF recovery however appear to be reduced in the ID setting.TCT-700
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Background: MitraClip therapy is emerging as a viable option for high-risk patients.
The aim of the study was to assess MitraClip and surgical repair results in octoge-
narians with degenerative mitral regurgitation (DMR).
Methods: Since October 2008, 46 octogenarians underwent isolated mitral repair for
DMR at our Institution using MitraClip or standard surgery. A retrospective
comparison was conducted.
Results: MitraClip was performed in 24 (52.2%) and surgery in 22 (44.8%) cases.
Baseline features for MitraClip and surgery respectively included: mean age 84.73.4
vs 81.81.6 years (p¼0.0004), median STS mortality 8.4 vs 5.7 (p¼0.02), NYHA>II
70.8% vs 40.9% (p¼0.04), mean creatinine 1.20.3 vs 0.90.3 mg/dL (p¼0.009),
chronic obstructive pulmonary disease 33% vs 9% (p¼0.04). The groups did not differacts/POSTER/Mitral Valve Disease and Treatment B213
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